NCT04487405 (OVAnex) is a clinical trial of OVAnex in Adnexal Mass, sponsored by Aspira Women's Health.

Who is sponsoring NCT04487405?

NCT04487405 is sponsored by Aspira Women's Health.

What drugs are being tested in NCT04487405?

Interventions in NCT04487405: OVAnex.

What condition does NCT04487405 study?

NCT04487405 studies Adnexal Mass.

Is NCT04487405 still recruiting?

NCT04487405 is currently terminated. Last updated 26 December 2023.

Last reviewed 2023-12-26 · How we verify

NCT04487405: OVAnex

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants

Terminated Last updated 26 December 2023

What this trial tests

trial testing OVAnex in Adnexal Mass in 721 participants. Terminated before completion.

Timeline

25 June 2020

Primary endpoint
15 December 2023

15 December 2023

Quick facts

Lead sponsor	Aspira Women's Health
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	721
Start date	25 June 2020
Primary completion	15 December 2023
Estimated completion	15 December 2023
Sites	9 locations across United States

Drugs / interventions tested

OVAnex

Conditions studied

Adnexal Mass — all drugs for Adnexal Mass →

Sponsor

Aspira Women's Health

Who can join

18 and older, female only, with Adnexal Mass. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.
Ghose A, McCann L, Makker S, Mukherjee U, et al · · 2024 · cited 75× · PMID 38435431 · DOI 10.1177/17588359241233225

Verify or expand the search:

Other recruiting trials for Adnexal Mass

Currently open trials in the same condition.

NCT06693596 — Masses in Young Patients - International Ovarian Tumour Analysis (MY-IOTA) · recruiting
NCT05761275 — Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach · NA · recruiting
NCT05051722 — Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer · recruiting

Other Aspira Women's Health trials

Trials by the same sponsor.

NCT05245695 — Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) · recruiting
NCT04668521 — Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04487405 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aspira Women's Health
Last refreshed: 26 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04487405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing